Scrip M&A Podcast: Why Did Biopharma M&A Metrics Decline During Q2 And Q3 episode artwork

EPISODE · Nov 14, 2024 · 37 MIN

Scrip M&A Podcast: Why Did Biopharma M&A Metrics Decline During Q2 And Q3

from Citeline Podcasts · host Norstella

Scrip senior writer Joseph Haas discusses recent merger-and-acquisition activity in the biopharma sector with Gerardo Ubaghs, CFO of Frontier Medicines, and Jason Silvers, CFO of Generate Biomedicines. The panel looks at why M&A activity metrics declined during both the second and third quarters despite a strong start to the year and apparent positive conditions for dealmaking, as well as what impact the US election results could have on M&A going forward.

Episode metadata supplied by the publisher feed · Published Nov 14, 2024

Embed this episode

NOW PLAYING

Scrip M&A Podcast: Why Did Biopharma M&A Metrics Decline During Q2 And Q3

0:00 37:21

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Citeline Podcasts?

This episode is 37 minutes long.

When was this Citeline Podcasts episode published?

This episode was published on November 14, 2024.

Can I download this Citeline Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!